LOS ANGELES, June 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or "the Company") (NYSE: BLCO) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Bausch + Lomb reported its financial results for Q1 2025 on April 30 ...

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Bausch + Lomb and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Bausch + Lomb and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On March ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other jur ...

For the quarter ended March 2025, Bausch + Lomb (BLCO) reported revenue of $1.14 billion, up 3.5% over the same period last year. EPS came in at -$0.07, compared to $0.07 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.15 billion, representing a surprise of -0.86%. The company delivered an EPS surprise of -333.33%, with the consensus EPS estimate being $0.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Group 1 - Bausch + Lomb reported a quarterly loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.03, and compared to earnings of $0.07 per share a year ago, representing an earnings surprise of -333.33% [1] - The company posted revenues of $1.14 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.86%, and this is an increase from year-ago revenues of $1.1 billion [2] - Bausch + Lomb shares have declined approximately 24% since the beginning of the year, while the S&P 500 has decreased by 5.5% [3] Group 2 - The earnings outlook for Bausch + Lomb is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for Bausch + Lomb is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $1.27 billion, and for the current fiscal year, it is $0.67 on revenues of $5 billion [7] Group 3 - The Medical Services industry, to which Bausch + Lomb belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Financial Performance - Total reported revenue for Q1 2025 was $1.137 billion, a 3% increase from $1.099 billion in Q1 2024, with a 5% increase on a constant currency basis[4] - GAAP net loss attributable to Bausch + Lomb for Q1 2025 was $212 million, compared to a net loss of $167 million in Q1 2024[13] - Adjusted EBITDA excluding Acquired IPR&D for Q1 2025 was $126 million, down from $180 million in Q1 2024, a decrease of $54 million[16] - Adjusted net income (non-GAAP) for Q1 2025 was $24 million, compared to a loss of $54 million in Q1 2024, resulting in an adjusted EPS of $0.07 versus a loss of $0.15[46] - Total revenues for Q1 2025 were $1,137 million, a 3.5% increase from $1,099 million in Q1 2024, driven by product sales of $1,133 million[45] - The net loss attributable to Bausch + Lomb Corporation for Q1 2025 was $212 million, compared to a net loss of $167 million in Q1 2024, with a diluted loss per share of $0.60 versus $0.48[45] - Adjusted EBITDA (non-GAAP) for Q1 2025 was $98 million, down from $180 million in Q1 2024, reflecting a decrease of 45.6%[50] Segment Performance - Vision Care segment revenue was $656 million, a 3% increase from $635 million in Q1 2024, with a 5% increase on a constant currency basis[9] - Surgical segment revenue was $214 million, a 9% increase from $197 million in Q1 2024, with an 11% increase on a constant currency basis[10] - Pharmaceuticals segment revenue remained flat at $267 million, with a 1% increase on a constant currency basis[11] - Vision Care segment revenue increased to $669 million in Q1 2025, up 5% from $635 million in Q1 2024[51] - Surgical segment revenue grew by 11% to $218 million in Q1 2025, compared to $197 million in Q1 2024[51] - Pharmaceuticals segment revenue remained stable at $269 million in Q1 2025, with a slight increase of 1% from $267 million in Q1 2024[51] Operational Costs - Operating loss for Q1 2025 was $83 million, compared to an operating income of $6 million in Q1 2024, a change of $89 million[12] - Cash flow used in operations for Q1 2025 was $25 million, down from $41 million in Q1 2024[14] - Cost of goods sold (excluding amortization and impairments) increased to $481 million in Q1 2025 from $423 million in Q1 2024, reflecting a 13.7% rise[45] - Selling, general and administrative expenses rose to $563 million in Q1 2025, up from $504 million in Q1 2024, marking an increase of 11.7%[45] - Research and development expenses were $86 million in Q1 2025, slightly up from $82 million in Q1 2024, indicating a 4.9% increase[45] - The company incurred $38 million in restructuring, integration, and transformation costs in Q1 2025, compared to $28 million in Q1 2024[50] Guidance and Future Outlook - Full-year 2025 revenue guidance updated to $5.000 billion - $5.100 billion, reflecting a constant currency growth of approximately 4.5% - 6.5%[18] - Bausch + Lomb's 2025 full-year guidance is based on current management expectations and includes anticipated growth in key products like XIIDRA® and MIEBO®[25] - The company is undergoing a separation from Bausch Health Companies Inc., which may involve transferring equity interests to shareholders, contingent on achieving targeted debt leverage ratios[25] - Future business development transactions may lead to recurring costs related to Acquired In-Process Research and Development (IPR&D) as the company continues to pursue growth opportunities[36] Risks and Challenges - Risks associated with the separation include potential business disruptions, regulatory approvals, and market conditions that may affect the transaction's completion[26] - The anticipated impact of tariffs and global supply chain disruptions is a concern for the company's revenue and expenses moving forward[26] - The company is actively managing the expected impact of inflation and interest rate fluctuations on its financial performance[26] - The voluntary recall of certain enVista® IOL products is expected to affect market supply, with enhanced inspection protocols in place to address quality concerns[26] Financial Metrics and Adjustments - The company reported a total of $191 million in non-GAAP adjustments for Q1 2025, compared to $158 million in Q1 2024[46] - Amortization of intangible assets decreased to $67 million in Q1 2025 from $74 million in Q1 2024[47] - The company utilized constant currency revenue growth metrics to assess performance, indicating that foreign exchange fluctuations can obscure underlying business trends[39] - Management emphasized the importance of adjusted financial metrics for evaluating operational performance and making strategic decisions[38] - The company has excluded costs related to share-based compensation and separation activities from its financial measures to provide clearer insights into operational performance[34]

Core Insights - Bausch + Lomb (BLCO) currently presents a better value opportunity compared to Danaher (DHR) based on various financial metrics and rankings [1][7] Valuation Metrics - BLCO has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while DHR has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for BLCO is 18.75, significantly lower than DHR's forward P/E of 25.14, suggesting BLCO is undervalued [5] - BLCO's PEG ratio stands at 0.75, while DHR's PEG ratio is 2.46, further indicating BLCO's better value proposition [5] - BLCO has a P/B ratio of 0.67 compared to DHR's P/B of 2.80, reinforcing the notion that BLCO is more undervalued [6] - BLCO's overall Value grade is B, while DHR's Value grade is D, highlighting the relative attractiveness of BLCO [6]

Patent and Regulatory Environment - As of February 12, 2025, the company owns or exclusively licenses approximately 2,584 granted patents worldwide, with about 465 being U.S. patents[52] - Approximately 78% of the company's issued patents will expire within the next 10 years, with 23 patents set to expire in both 2025 and 2026, and 36 patents in 2027[52] - The company relies on a combination of regulatory and patent rights to protect the value of its investment in product development[51] - The U.S. Hatch-Waxman Act provides non-patent regulatory exclusivity for five years from the first FDA approval of a new drug compound[54] - The company has approximately 127 pending U.S. patent applications, indicating ongoing innovation efforts[52] - The FDA may designate a product as an orphan drug if it treats a disease affecting fewer than 200,000 individuals in the U.S., granting seven years of marketing exclusivity[58] - The company is subject to extensive government regulations regarding the research, development, testing, and marketing of pharmaceutical products and medical devices[63] - Compliance with manufacturing regulations, including good manufacturing practices, is enforced by the FDA and Health Canada[67] - The company faces periodic audits of its facilities by regulatory agencies, ensuring adherence to compliance standards[68] - Price control restrictions on pharmaceutical products are present in many countries where the company operates[69] Workforce and Operations - The company operates in approximately 100 countries with a global commercial team of about 4,300 employees[89] - In the United States, the company has around 1,150 employees dedicated to selling and marketing contact lenses, lens care, consumer eye health, surgical, and prescription pharmaceutical products[90] - The international commercial footprint includes approximately 3,150 employees and a network of distribution partners[90] - As of December 31, 2024, the company had approximately 13,500 employees, with 7,200 in production and 4,300 in sales and marketing[104] - The company launched a new global performance management program in 2024 to enhance employee performance monitoring and alignment[113] Financial Performance and Risks - In 2024, customers accounting for 10% or more of total revenues were McKesson Corporation and Cardinal Health, Inc., each contributing 10%[93] - Approximately 37% of product sales for 2024 are produced in total or in part by third-party manufacturers under manufacturing arrangements[102] - The company’s revenues tend to be weighted toward the second half of the year, with first-quarter sales typically lower due to patient co-pays and deductibles resetting[118] - As of December 31, 2024, the company had $3,441 million in variable rate debt and $1,400 million in fixed rate debt[578] - A 100 basis-points increase or decrease in interest rates would have an annualized pre-tax effect of approximately $34 million on earnings and cash flows[578] - The estimated fair value of the company's fixed rate debt as of December 31, 2024, was $1,449 million[578] - A 1% change in foreign currency exchange rates would impact shareholders' equity by approximately $27 million[577] - The company is exposed to multiple foreign currencies, including the Euro, Chinese yuan, Russian ruble, and Japanese yen[577] - Further strengthening of the U.S. dollar or devaluation of foreign currencies will negatively impact reported revenue and results[577] - If interest rates increase by 100 basis-points, the fair value of fixed rate debt would decrease by approximately $35 million[578] - If interest rates decrease by 100 basis-points, the fair value of fixed rate debt would increase by approximately $31 million[578] - Changes in interest rates could adversely affect the company's earnings and cash flows due to its variable rate debt[578] Compliance and Governance - The company is subject to extensive U.S. federal and state health care marketing and fraud regulations, including the federal False Claims Act and Anti-Kickback Statute, which impose significant compliance obligations[70] - The company must comply with the Health Insurance Portability and Accountability Act (HIPAA) and various state laws regarding the privacy and security of health-related information, which may require substantial costs for compliance[73] - The General Data Protection Regulation (GDPR) imposes strict obligations on the processing of personal data, with potential fines of up to 4% of global annual revenue or €20 million for violations[76] - The company is subject to the Personal Information Protection Law (PIPL) in China, which regulates the transfer of personal data outside of China, effective from March 1, 2023[79] - The regulatory framework for data privacy and security is rapidly evolving, which may lead to increased compliance costs and risks for the company[82] - The company is developing an integrated ESG program to comply with evolving regulations related to environmental, social, and governance matters[86] Corporate Social Responsibility - The ONE by ONE Recycling program has collected over 94 million used contact lenses and related items since its launch in November 2016[117] - The company’s commitment to corporate social responsibility includes initiatives aimed at disease prevention and improving patient outcomes globally[116] Supply Chain and Manufacturing - The company operates 23 manufacturing facilities across 10 countries, including the U.S., Ireland, and China, focusing on specific product categories[98] - The company’s global supply team is actively managing inflationary and supply-chain challenges due to ongoing macroeconomic conditions[103] - The company faces pressures from government authorities and third-party payors to limit or regulate the price of medical products, which can result in lower average realized prices[83]

Financial Data and Key Metrics Changes - The company reported total revenue of $1.28 billion for Q4 2024, reflecting an 11% increase and 10% organic growth. For the full year, total revenue was $4.791 billion, representing a 17% increase and 10% organic growth [24][25]. - Adjusted gross margin for Q4 was 62.5%, and for the full year, it was 62.6%, up 160 basis points compared to the previous year [39]. - Adjusted EBITDA for Q4 was $259 million, representing a 14% growth year-over-year, while for the full year, it was $878 million, up 20% compared to 2023 [40]. Business Line Data and Key Metrics Changes - Vision Care revenue for Q4 was $723 million, an 11% increase, with full-year revenue of $2.739 billion, up 10% [26]. - The Surgical segment reported Q4 revenue of $231 million, a 15% increase, with full-year revenue of $843 million, representing 11% growth [32]. - The Pharma segment generated $326 million in revenue for Q4, a 7% increase, and $1.209 billion for the full year, reflecting a 45% growth [34]. Market Data and Key Metrics Changes - The U.S. contact lens revenue grew by 17% in Q4, while international revenue increased by 11%. For the full year, U.S. revenue was up 12% and international revenue was up 11% [30]. - The company saw a 75% growth in Daily SiHy lenses in Q4, contributing to the overall contact lens revenue growth of 13% for the quarter [29]. Company Strategy and Development Direction - The company is focused on innovation and execution, with a commitment to long-term growth and a robust pipeline of new products [10][11]. - The strategy includes optimizing manufacturing processes and leveraging AI to enhance sales force effectiveness [9]. - The company aims to maintain its leadership position in the eye care market by addressing unmet needs and expanding its product offerings [8][12]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fundamentals of the eye care market, expecting each segment to deliver growth in 2025 [42]. - The company anticipates currency headwinds of approximately $100 million to revenue and $20 million to adjusted EBITDA in 2025 due to the strengthening U.S. dollar [44]. - Management highlighted the importance of continued investment in R&D and direct-to-consumer campaigns to drive future growth [45][48]. Other Important Information - The company expects full-year revenue for 2025 to be in the range of $4.95 billion to $5.05 billion, reflecting constant currency growth of approximately 5.5% to 7.5% [42]. - Adjusted EBITDA guidance for 2025 is set between $900 million to $950 million, excluding potential one-time IPR&D charges [43]. Q&A Session Summary Question: Insights on customer growth and execution - Management noted significant improvements in operational excellence and customer service, leading to a 10% organic revenue growth CAGR over the past two years [75][76]. Question: Contact lens growth sustainability - Management expressed optimism about the contact lens market, highlighting strong growth driven by new products and direct-to-consumer capabilities [87][88]. Question: Expectations for Miebo and Xiidra - Management indicated high expectations for Miebo's continued growth and noted that Xiidra is expected to see TRx growth momentum in 2025 [100][102]. Question: Market share and transitioning customers - Management confirmed a balanced approach between transitioning existing customers and acquiring new fits, contributing to overall growth [111]. Question: Guidance for 2025 revenue growth - Management explained that the guidance reflects a reasonable starting point, factoring in market dynamics and the impact of the Inflation Reduction Act [116][117].